Ascletis Pharma, Inc. (HK:1672) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Ascletis Pharma Inc. revealed promising Phase I study results for its innovative weight loss drug, ASC47, showcasing significant fat reduction and muscle preservation compared to existing treatments. The study in Australia highlighted ASC47’s potential for once-monthly administration due to its 21-day half-life and impressive tolerance profile with minimal adverse effects. These findings position ASC47 as a compelling candidate in the obesity treatment market, with further studies underway.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue